


**Product Name** : Acalabrutinib  
**Cat. No.** : PC-45383  
**CAS No.** : 1420477-60-6  
**Molecular Formula** : C<sub>26</sub>H<sub>23</sub>N<sub>7</sub>O<sub>2</sub>  
**Molecular Weight** : 465.5065  
**Target** : BTK  
**Solubility** : DMSO: ≥ 31 mg/mL



## Biological Activity

Acalabrutinib (ACP-196) is a potent, irreversible, covalent second-generation **BTK** inhibitor with IC<sub>50</sub> of 3 nM. Acalabrutinib (ACP-196) is more potent and selective than ibrutinib, and does not inhibit EGFR, Itk or Txk. Acalabrutinib (ACP-196) inhibits tyrosine phosphorylation of downstream targets of ERK, IKB, and AKT, in the in vitro signaling assay on primary human CLL cells. Acalabrutinib (ACP-196) inhibits anti-IgM-induced CD86 expression in CD19+ splenocytes with an ED<sub>50</sub> of 0.34 mg/kg in mice. Acalabrutinib (ACP-196) has promising safety and efficacy profiles for CLL treatment; orally active.

## References

- Byrd JC, et al. *N Engl J Med*. 2016 Jan 28;374(4):323-32.
- Herman SEM, et al. *Clin Cancer Res*. 2017 Jul 15;23(14):3734-3743.
- Niemann CU, et al. *Clin Cancer Res*. 2017 Jun 23. pii: clincanres.0650.2017.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com